Prothena (PRTA) Competitors $8.21 -0.22 (-2.61%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.22 +0.01 (+0.12%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. APGE, CDTX, BEAM, BHVN, TWST, IMCR, AUPH, TVTX, ARDX, and WVEShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Apogee Therapeutics (APGE), Cidara Therapeutics (CDTX), Beam Therapeutics (BEAM), Biohaven (BHVN), Twist Bioscience (TWST), Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Ardelyx (ARDX), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Apogee Therapeutics Cidara Therapeutics Beam Therapeutics Biohaven Twist Bioscience Immunocore Aurinia Pharmaceuticals Travere Therapeutics Ardelyx WAVE Life Sciences Apogee Therapeutics (NASDAQ:APGE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment. Which has higher valuation and earnings, APGE or PRTA? Prothena has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-8.93Prothena$135.16M3.27-$122.31M-$5.64-1.46 Is APGE or PRTA more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Apogee Therapeutics' return on equity of -34.65% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Prothena -2,929.30%-62.17%-54.43% Do insiders & institutionals believe in APGE or PRTA? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 9.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend APGE or PRTA? Apogee Therapeutics presently has a consensus target price of $97.29, indicating a potential upside of 163.79%. Prothena has a consensus target price of $19.75, indicating a potential upside of 140.56%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Apogee Therapeutics is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor APGE or PRTA? In the previous week, Apogee Therapeutics and Apogee Therapeutics both had 12 articles in the media. Apogee Therapeutics' average media sentiment score of 1.32 beat Prothena's score of 0.72 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, APGE or PRTA? Apogee Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. SummaryApogee Therapeutics beats Prothena on 10 of the 14 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$453.79M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-1.4621.4375.3425.98Price / Sales3.27429.47514.55181.19Price / CashN/A46.6837.5660.44Price / Book0.919.6112.156.29Net Income-$122.31M-$53.29M$3.29B$271.07M7 Day Performance-3.98%0.13%0.74%3.87%1 Month Performance1.99%5.61%4.82%4.88%1 Year Performance-62.87%10.49%60.58%26.12% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.3884 of 5 stars$8.21-2.6%$19.75+140.6%-60.4%$453.79M$135.16M-1.46130News CoverageAnalyst RevisionAPGEApogee Therapeutics2.928 of 5 stars$36.37-0.7%$97.29+167.5%-25.0%$1.68BN/A-8.8191News CoveragePositive NewsCDTXCidara Therapeutics3.2753 of 5 stars$65.39+0.2%$64.14-1.9%+478.1%$1.66B$1.27M-5.8890Positive NewsBEAMBeam Therapeutics2.8753 of 5 stars$16.36-2.9%$48.45+196.2%-15.6%$1.66B$63.52M-3.64510BHVNBiohaven3.2762 of 5 stars$15.35-1.1%$54.23+253.2%-61.0%$1.63BN/A-2.00239Trending NewsTWSTTwist Bioscience3.9713 of 5 stars$26.97+1.4%$49.40+83.2%-43.2%$1.63B$312.97M-18.60990News CoverageIMCRImmunocore1.8645 of 5 stars$32.22-0.1%$56.89+76.6%+6.7%$1.62B$310.20M-80.55320AUPHAurinia Pharmaceuticals2.9211 of 5 stars$11.99-0.7%$12.00+0.1%+93.6%$1.58B$235.13M27.88300News CoveragePositive NewsTVTXTravere Therapeutics2.9964 of 5 stars$17.50-1.1%$33.43+91.0%+86.3%$1.56B$233.18M-8.58460News CoverageAnalyst ForecastARDXArdelyx4.6295 of 5 stars$6.36-0.3%$11.50+80.8%+6.3%$1.53B$333.61M-27.6590News CoveragePositive NewsWVEWAVE Life Sciences4.555 of 5 stars$9.60-3.3%$20.27+111.1%+18.9%$1.53B$108.30M-10.67240Positive News Related Companies and Tools Related Companies Apogee Therapeutics Competitors Cidara Therapeutics Competitors Beam Therapeutics Competitors Biohaven Competitors Twist Bioscience Competitors Immunocore Competitors Aurinia Pharmaceuticals Competitors Travere Therapeutics Competitors Ardelyx Competitors WAVE Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
